Inovio Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview

Inovio Pharmaceuticals

10/08/2026 22:32

Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to  show no change in quarterly revenue when it reports  results on August 12 for the period ending June 30 2026

​LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of 22 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $2.50, about 274.3% above its last closing price of $0.67
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.34
-0.35
-0.28
Beat
20
Dec. 31 2026
-0.32
-0.36
0.06
Beat
116.8
Sep. 30 2025
-0.41
-0.42
-0.87
Missed
-105.6​
Jun. 30 2025
-0.60
-0.61
-0.61
Met
-0.1
​​Mar. 31 2025
-0.75
-0.74
-0.41
Beat
44.4
Dec. 31 2024
-0.79
-0.84
-0.60
Beat
28.3​
Sep. 30 2024
-1.14
-1.15
-0.89
Beat
22.6
Jun. 30 2024
-1.12
-1.10
-1.19
Missed
-8
This summary was machine generated August 10 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)